Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1669347 | 1.00 | KMT2A (0.52) | KMT2AALDH1A1LMNAMAPTNPC1 | |
| SCHEMBL31477687 | 1.00 | KMT2A (0.52) | KMT2AALDH1A1LMNAMAPTNPC1 | |
| Hydrochloric Acid SCHEMBL9694444 | 0.99 | KMT2A (0.51) | KMT2AALDH1A1LMNAMAPTNPC1 | |
| Hydrochloric Acid SCHEMBL9694453 | 0.99 | KMT2A (0.51) | KMT2AALDH1A1LMNAMAPTNPC1 | |
| SCHEMBL16563740 | 0.86 | ALDH1A1 (0.61) | KMT2AALDH1A1LMNAMAPTNPC1 | |
| SCHEMBL16711989 | 0.86 | ALDH1A1 (0.61) | KMT2AALDH1A1LMNAMAPTNPC1 | |
| SCHEMBL9693813 | 0.86 | ALDH1A1 (0.61) | KMT2AALDH1A1LMNAMAPTNPC1 | |
| SCHEMBL7697932 | 0.84 | MAPT (0.51) | KMT2AALDH1A1LMNAMAPTNPC1 | |
| SCHEMBL12890441 | 0.83 | KMT2A (0.52) | KMT2AALDH1A1LMNAMAPTNPC1 | |
| SCHEMBL9693888 | 0.83 | NPC1 (0.60) | KMT2AALDH1A1LMNAMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110627724-A | Pyrazole derivative calcium release-activated calcium channel modulators and methods of treating non-small cell lung cancer | 理森制药股份公司 | 2019-12-31 | — | — | CN | disclosed |
| US-20190248791-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | RHIZEN PHARMACEUTICALS SA (CH) | 2019-08-15 | — | — | US | disclosed |
| US-10174034-B2 | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | RHIZEN PHARMACEUTICALS SA (CH) | 2019-01-08 | — | — | US | disclosed |
| EP-2509974-B1 | PYRAZOLES DERIVATIVES MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | RHIZEN PHARMACEUTICALS S A (CH) | 2018-04-11 | — | — | EP | disclosed |
| US-20150291588-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | RHIZEN PHARMACEUTICALS SA (CH) | 2015-10-15 | — | — | US | disclosed |
| US-9056863-B2 | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof | H. LUNDBECK A/S (DK) | 2015-06-16 | — | — | US | disclosed |
| US-8993612-B2 | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | RHIZEN PHARMACEUTICALS SA (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20140235645-A1 | Pyridine Compounds and Uses Thereof | H. LUNDBECK A/S (DK) | 2014-08-21 | — | — | US | disclosed |
| EP-2763989-A1 | PYRIDINE COMPOUNDS AND USES THEREOF | H. Lundbeck A/S (DK) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013034761-A1 | PYRIDINE COMPOUNDS AND USES THEREOF | H. LUNDBECK A/S (DK) | 2013-03-14 | — | — | WO | disclosed |
| EP-2509974-A1 | PYRAZOLES DERIVATIVES MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON- SMALL CELL LUNG CANCER | Rhizen Pharmaceuticals S.A. (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20110112058-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | US | disclosed |
| WO-2011042798-A1 | PYRAZOLES DERIVATIVES MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON- SMALL CELL LUNG CANCER | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235645-A1 | Pyridine Compounds and Uses Thereof | ATP6V1B2, NDUFS5, MT-ND5 | KMT2A 1889/4885ALDH1A1 328/4885LMNA 4038/4885 |
| US-20110112058-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | ORAI1, CACNB2, CACNB1 | KMT2A 4626/4885ALDH1A1 3914/4885LMNA 1452/4885 |
| US-20190248791-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | ORAI1, CACNB2, CACNB1 | KMT2A 4626/4885ALDH1A1 3914/4885LMNA 1452/4885 |
| US-20150291588-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | ORAI1, CACNB2, CACNB1 | KMT2A 4626/4885ALDH1A1 3914/4885LMNA 1452/4885 |
| US-10174034-B2 | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | ORAI1, CACNA1E, CACNB2 | KMT2A 4669/4885ALDH1A1 3852/4885LMNA 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.